Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Apple Restores Telegram to App Store After Content Policy Violation 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
SOUTH SAN FRANCISCO, Calif., April 03, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on April 2, 2018, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 750 shares of the Company’s common stock with a per share exercise price of $44.20, the closing trading price on the grant date, and a restricted stock unit award for 500 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employee entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock options and restricted stock unit awards described above) for issuance under the Plan, which was approved by the Company’s Board of Directors in January 2017.
About Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
